私は医師になって臨床の場ではたらき始めた後

今から30年ほど前から研究者としても歩みを始めました。

その人生の半分ちかくにおよぶ間ずっと

特に興味をもっていたのが免疫学の分野です。

今でも

T細胞、B細胞、樹状細胞、マクロファージなどの免疫細胞

そして

サイトカイン、その受容体であるサイトカインレセプター、そして

その細胞内下流のJAK/STATシグナル伝達系を介しての

細胞や組織の営みに思いを馳せると

夢の中にまで

その世界にどっぷり漬かってしまいます。

その経験とアイディアが

現在私たちが取り組んでいる

NMN点滴療法

ヒト間葉系幹細胞培養上清(エクソソーム)療法

水素ガス吸入療法

に活かされているのです。

 

以下にわたしが携わった

免疫学領域の研究論文を掲載します。

興味ある方は読んでみてください。

 

Hata H, Matsuzaki H, Matsuno F, Sonoki T, Takemoto S, Kuribayashi N, Nagasaki A, Takatsuki K: Establishment of a monoclonal antibody to plasma cells: A comparison with CD38 and PCA-1.  Clinical Experimental Immunology 1994; 96:370–375.

Hata H, Matsuzaki H, Sonoki T, Takemoto S, Kuribayashi N, Nagasaki A, Takatsuki K: Establishment of a CD45-positive immature plasma cell line from an aggressive multiple myeloma with high serum lactate dehydrogenase.  Leukemia 1994; 8:1768–1773.

Takemoto S, Mulloy JC, Cereseto A, Migone TS, Patel BKR, Matsuoka M, Yamaguchi K, Takatsuki K, Kamihira S, White JD, Leorard WJ, Waldmann T, Franchini G: Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins.  Proceedings of the National Academy of Sciences of The United States of America 1997; 94 (25):13897–13902.

Takemoto S, Al-Dahoodi Z, Moriki T, Taguchi H: Dendritic cells and adult T-cell leukemia/lymphoma.  Annals of Oncology 2002; 13 (Supple. 2):106.

Al-Dahoodi ZM, Takemoto S, Kataoka S, Taguchi H: Dysfunction of dendritic and T cells as the cause of immune suppression in HTLV-I infected individuals.  Journal of Clinical Experimental Hematopathology 2003; 43:43–48.

Al-Dahoodi ZM, Takemoto S, Machida H, Furuya M, Miyoshi I, Taguchi H: Generation of functional monocyte-derived dendritic cells from HTLV-I infected rabbits: Therapeutic approach using a dendritic cell vaccine.  Journal of Clinical Experimental Hematopathology 2004; 44:17–24.

Horino T, Sasaoka A, Takao T, Taguchi T, Maruyama H, Ito H, Takemoto S, Taguchi H, Hashimoto K: Immune thrombocytopenic purpura associated with rheumatoid arthritis: case report. Clinical Rheumatology 2005; 24:641–644.

Takahashi T, Takemoto S, Kiyasu K, Yamamoto H, Tani T, Miyoshi I, Taguchi H, Moriki T, Miyazaki E, Enzan H: Treatment for HTLV-I associated arthropathy: a case study and synovial tissue culture analysis. Rheumatology International Clinical and Experimental Investigations 2005; 26:74–79.

Nishioka C, Takemoto S, Kataoka S, Yamanaka S, Moriki T, Shoda M, Watanabe T, Taguchi H: Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Science 2005; 96:810–815.

Takemoto S, Hidaka M, Nagakura S, Sakai T, Matsui T, Kawakita T, Inoue Y, Tsukamoto A, Kiyokawa T, Kawano F: Allogeneic hematopoietic stem cell transplantation as consolidation therapy for adult T cell leukemia/lymphoma patients: A single-center experience in 35 patients. Blood 2007; 110:339B.

Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation. Hidaka M, Iwasaki S, Matsui T, Kawakita T, Inoue Y, Sakai T, Harada N, Takemoto S, Nagakura S, Kiyokawa T, Takahashi M, Saibara T, Onishi S, Kawano F. Bone Marrow Transplant. 2010 May;45(5):912–8.

Pornkuna R, Takemoto S, Uzawa K, Morita K, Kawano F. Proteins function for anti-senescence and monoclonal proliferation of ATL cells. Retrovirology. 2011;8(Suppl 1): A127.

Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R. Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study. J Clin Oncol. 2012 Mar 10;30(8):837–842.

Tamai Y, Hasegawa A, Takamori A, Sasada A, Tanosaki R, Choi I, Utsunomiya A, Maeda Y, Yamano Y, Eto T, Koh KR, Nakamae H, Suehiro Y, Kato K, Takemoto S, Okamura J, Uike N, Kannagi M. Potential contribution of a novel Tax epitope-specific CD4+ T cells to graft-versus-Tax effect in adult T cell leukemia patients after allogeneic hematopoietic stem cell transplantation. J Immunol 2013 Apr 15;190(8):4382–4392.

Pornkuna R, Takemoto S. A lack of cellular senescence, formation of microenvironment, and role of soluble CD30 in development of adult T-cell leukemia/lymphoma. J Hematol Thrombo Dis 2014;2(4): doi.org/10.4172/2329-8790. 1000151.

Pornkuna R, Nishioka C, Takemoto S. What is the role of soluble cytokine receptors in adult T-cell leukemia/lymphoma? J Hematol Thrombo Dis 2014;2(5): doi.org/10.4172/2329-8790. 1000154.

Takemoto S, Pornkuna R. Soluble CD30 and peripheral blood or pulmonary involvement of adult T-cell leukemia/lymphoma. Integr Cancer Sci Therap 2014;1(2):10–11, doi: 10.15761/ICST.1000103.

Takemoto S, Pornkuna R. Mutualism among HTLV-1-infected different type of cells or among other virus-infected cells. J Hematol Thrombo Dis 2014;2(6): doi.org/10.4172/2329-8790. 1000164.

Pornkuna R, Takemoto S, Hidaka M, Kawano F, Haga Y. Clinical value of serum soluble CD30 levels in adult T-cell leukemia/lymphoma. J Hematol Thrombo Dis 2014;2(6): doi.org/10.4172/2329-8790. 1000167.

Takemoto S. CD25+, CD30+adult T-cell leukemia/lymphoma cells, virus-infected cells or regulatory T cells? J Hematol Thrombo Dis 2014;2(6): doi.org/10.4172/2329-8790. 1000175.

Takemoto S. Human retroviruses and soluble CD30 levels of patients. J Cell Sci Ther 2014;5(5): doi.org/10.4172/2157-7013.1000184.

Takemoto S, Morimatsu Y, Pornkuna R, Murayama T, Kawano F. CD30+ cells in lung of indolent type adult T-cell leukemia/lymphoma and elevated serum levels of soluble CD30 associated with acute crisis and relapse of disease. J Leuk 2014;2(5): doi.org/10.4172/2329-6917. 1000166.

Takemoto S. Serum soluble CD25 and CD30 levels as a biomarker in adult T-cell leukemia/lymphoma patients undergoing allogeneic hematopoietic stem cell transplantation. J Hematol Thrombo Dis 2015;3(1): doi.org/10.4172/2329-8790. 1000182.

Takemoto S, Kozako T, Pornkuna R. Shedding by ADAM10 and ADAM17 is associated with progression of adult T-cell leukemia/lymphoma. Integr Cancer Sci Therap 2015; 2: DOI: 10.15761/ICST.1000118

Takemoto S. My views and thoughts on Translational Medicine. Transl Med 2015;5:147 doi: 10.4172/2161-1025.1000147

Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, Ueda R. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive ATL: a randomized phase II study. Br J Haematol 2015;Mar 10;30(8):837–842.

Takemoto S, Pornkuna R, Nishioka C. Serum soluble CD30 levels to detect activation and aggression status of adult T-cell leukemia/lymphoma cells. J Hematol Thrombo Dis 2015;3:205. doi: 10.4172/2329-8790.1000205

Takemoto S, Iwanaga M, Sagara Y, Watanabe T. Plasma soluble CD30 as a possible marker of adult T-cell leukemia in HTLV-1 carriers: a nested case-control study. Asian Pacific Journal of Cancer Prevention 2015;16(18):8253–8258.

Ishida T, Utsunomiya A, Jo T, Yamamoto K, Kato K, Yoshida S, Takemoto S, Suzushima H, Kobayashi Y, Imaizumi Y, Yoshimura K, Kawamura K, Takahashi T, Tobinai K, Ueda R. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies. Cancer Sci. 2017 Oct;108(10):2022-2029. doi: 10.1111/cas.13343. Epub 2017 Aug 28.

Ishida T, Jo T, Takemoto S, Suzushima H, Suehiro Y, Choi I, Yoshimitsu M, Saburi Y, Nosaka K, Utsunomiya A, Kobayashi Y, Yamamoto K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Imada K, Kato K, Moriuchi Y, Yoshimura K, Takahashi T, Tobinai K, Ueda R. Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2019 Feb;184(3):479-483. doi: 10.1111/bjh.15123. Epub 2018 Feb 7.

Nakahata S, Syahrul C, Nakatake A, Sakamoto K, Yoshihama M, Nishikata I, Ukai Y, Matsuura T, Kameda T, Shide K, Kubuki Y, Hidaka T, Kitanaka A, Ito A, Takemoto S, Nakano N, Saito M, Iwanaga M, Sagara Y, Mochida K, Amano M, Maeda K, Sueoka E, Okayama A, Utsunomiya A, Shimoda K, Watanabe T, Morishita K. Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma. Haematologica. 2021 Feb 1;106(2):532-542. doi: 10.3324/haematol.2019.234096.